Table 6.
Comparison of clinical characteristics in subjects with no MetS components based on whether they were with or without hepatic steatosis.
| Characteristics | Controlled attenuation parameter (dB/m) | p | |
|---|---|---|---|
| <238 | ≥238 | ||
| n | 212 | 71 | — |
| Age (years) | 41.2 ± 11.3 | 45.4 ± 13.2 | 0.011 |
| Gender, male, n (%) | 27 (12.7%) | 15 (21.1%) | 0.085 |
| Body mass index (kg/m2) | 21.5 ± 2.1 | 22.7 ± 2.2 | 0.000 |
| Waist circumference (cm) | 74.4 ± 6.0 | 78.3 ± 5.6 | 0.000 |
| Waist-to-hip ratio | 0.82 ± 0.05 | 0.85 ± 0.05 | 0.000 |
| Neck circumference (cm) | 32.5 (31.0, 33.8) | 33.5 (32.0, 35.5) | 0.001 |
| Systolic pressure (mmHg) | 110 (106, 120) | 110 (107, 120) | 0.484 |
| Diastolic pressure (mmHg) | 68 (62, 72) | 69 (65, 72) | 0.558 |
| Drinking status, n (%) | 39 (18.4%) | 11 (15.5%) | 0.720 |
| Smoking status, n (%) | 3 (1.4%) | 1 (1.4%) | 1.000 |
| Dyslipidemia, n (%) | 23 (10.8%) | 14 (19.7%) | 0.055 |
| Controlled attenuation parameter (dB/m) | 206 (189, 224) | 259 (246, 280) | 0.000 |
| Liver stiffness measurement (kPa) | 3.8 (3.3, 4.4) | 3.7 (3.3, 4.4) | 0.197 |
| Fasting plasma glucose (mmol/L) | 4.9 (4.6, 5.1) | 4.9 (4.7, 5.3) | 0.071 |
| Cholesterol (mmol/L) | 4.90 (4.40, 5.40) | 5.00 (4.60, 5.60) | 0.142 |
| Triglyceride (mmol/L) | 0.82 (0.65, 1.04) | 0.94 (0.75, 1.22) | 0.002 |
| LDL-c (mmol/L) | 3.26 ± 0.67 | 3.43 ± 0.64 | 0.122 |
| HDL-c (mmol/L) | 1.61 ± 0.29 | 1.56 ± 0.35 | 0.280 |
| Alanine transaminase (U/L) | 15 (12, 20) | 17 (13, 22) | 0.077 |
| Aspartate transaminase (U/L) | 20 (18, 23) | 21 (18, 25) | 0.328 |
| Creatinine (μmol/L) | 58 (53, 67) | 60 (54, 72) | 0.069 |
| Estimated glomerular filtration rate (ml/min/1.73 m2) | 102.3 ± 19.0 | 96.7 ± 16.5 | 0.031 |
| Uric acid (μmol/L) | 295 (251, 346) | 334 (273, 381) | 0.005 |
| Adiponectin (μg/ml) | 20.6 (12.2, 29.7) | 10.7 (6.8, 20.3) | 0.000 |
| Fasting serum insulin (μU/ml) | 4.14 (2.96, 5.74) | 5.32 (3.72, 6.61) | 0.018 |
| White blood cell count (×109/L) | 5.8 (5.0, 6.7) | 6.3 (4.8, 7.3) | 0.041 |
| TyG | 4.38 (4.25, 4.51) | 4.43 (4.31, 4.59) | 0.001 |
| METS-IR | 27.1 (24.8, 29.4) | 28.9 (25.5, 31.4) | 0.011 |
| HOMA-IR | 0.87 (0.63, 1.26) | 1.09 (0.79, 1.47) | 0.023 |
MetS, metabolic syndrome; HOMA-IR, homeostatic model assessment of insulin resistance; TyG, the product of fasting triglycerides and glucose; METS-IR, metabolic score for insulin resistance; LDL-c, low-density lipoprotein cholesterol; HDL-c, high-density lipoprotein cholesterol.